According to the results of DESTINY-Lung01 and Lung02 trials, FDA approved T-DXd at 5.4 mg/kg dosing as new standard-of-care treatment for patients with previously treated HER2-mutant NSCLC [30]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.